I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at the age of 46.

Mavenclad may help manage coexisting autoimmune diseases alongside MS, potentially reducing the need for extra drugs.

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

Reports of cases detail the development of thyroid eye disease 3-5 years following treatment of MS with immunomodulatory ...

Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...

Effective management of multiple sclerosis (MS) relies heavily on sustained use of disease-modifying therapies (DMTs) to reduce relapse frequency, slow disability progression and preserve quality of ...

Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...

Daily propionic acid supplements lowered levels of a nerve damage marker in people with MS, but clinical benefits remain ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

The latest PBS stoush with drugmakers means thousands of people with MS are at risk of being forced to pay $33,000 a year for ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...